NASDAQ : MXCT
MaxCyte, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 1.73 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 178.55M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 149.65M |
| Enterprise Value | 61.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 103.21M |
| Shares Outstanding | 103.21M |
| Shares Change (YoY) | +0.95% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 58.67% |
| Float | 93.72M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.82 |
| Forward PS | 4.75 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.26 |
| Quick Ratio | 11.08 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -20.39% |
| Return on Assets (ROA) | -10.64% |
| Return on Invested Capital (ROIC) | -11.17% |
| Return on Capital Employed (ROCE) | -19.70% |
| Weighted Average Cost of Capital (WACC) | 11.16% |
| Revenue Per Employee | $341,220 |
| Profits Per Employee | -$391,604 |
| Employee Count | 91 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.82 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -5.84% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 55.34 |
| Average Volume (20 Days) | 1,634,853 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.83M |
| Short Previous Month | 1.09M |
| Short % of Shares Out | 1.77% |
| Short % of Float | 1.95% |
| Short Ratio (days to cover) | 1.81 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 31.05M |
| Gross Profit | 24.60M |
| Operating Income | -34.43M |
| Pretax Income | -35.64M |
| Net Income | -35.64M |
| EBITDA | -30.29M |
| EBIT | -34.43M |
| Loss Per Share | -$0.33 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 105.69M |
| Total Debt | 17.25M |
| Net Cash | 88.44M |
| Net Cash Per Share | $0.86 |
| Equity (Book Value) | 158.75M |
| Book Value Per Share | 1.50 |
| Working Capital | 111.38M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.98M |
| Capital Expenditures | -665,000 |
| Depreciation & Amortization | 4.14M |
| Net Borrowing | n/a |
| Free Cash Flow | -23.64M |
| FCF Per Share | -$0.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | 79.23% |
| Operating Margin | -110.88% |
| Pretax Margin | -114.77% |
| Profit Margin | -114.77% |
| EBITDA Margin | -97.54% |
| EBIT Margin | -110.88% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.95% |
| Shareholder Yield | -0.95% |
| Earnings Yield | -23.02% |
| FCF Yield | -15.80% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.11 |
| Price Target Difference | 183.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 9.91% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.46 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |